A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease
- Bonuccelli, U
- Meco, G
- Fabbrini, G
- Tessitore, A
- PIERANTOZZI, MARIANGELA
- Stocchi, F
- Ceravolo, R
- CALTAGIRONE, CARLO
- Silvestrini, M
- Morgante, F
- Ruggieri, S
- Avanzino, L
- Guadagna, M
- Dell'Agnello, G
- Rossi, A
- Spezia, R
- Mancini, M.
DOIAbstract
Depression is a comorbidity affecting quality of life (QoL) in patients with Parkinson's disease (PD) and requires appropriate treatment. This study evaluated the tolerability, safety, and efficacy of duloxetine 60 mg once daily for 12 weeks in PD patients with major depressive disorder (MDD). Research and design methods: Non-comparative, open-label, multi-center study
Add to ORKG